Current Edition

clinical

Patients Regain Sight With Stem Cell Treatment In U.K. Clinical Trial

Nearly three years ago, 86-year-old Douglas Waters developed severe vision problems. He was diagnosed with severe wet age-related macular degeneration(AMD), a chronic eye disease that causes blurred …

Continue Reading →
Crohn's disease

TiGenix announces publication in Gastroenterology of 52-week results of the Phase III ADMIRE-CD trial of Cx601

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop …

Continue Reading →
application

CRISPR Therapeutics Announces Planned European Clinical Trial

CRISPR Therapeutics today announced the submission of a Clinical Trial Application (CTA) today for CTX001 in β-thalassemia. CTX001 is an investigational CRISPR gene-edited autologous hematopoietic …

Continue Reading →
cancer

JW Pharma releases cancer treatment trial results

South Korea based JW Pharmaceuticals recently presented phase 1a/1b clinical trial results for CWP291, a target anticancer treatment that uses Wnt signaling pathway, at the …

Continue Reading →
clinical trial

Plasticell and Anthony Nolan to partner in clinical trials of ex vivo expanded cord blood stem cells

Plasticell, a developer of innovative stem cell technologies and cell therapies, today announced it will collaborate with Anthony Nolan, a leading research organisation dedicated to …

Continue Reading →
biopharmaceutical

TiGenix to present positive 52-week Phase III Cx601 data at EHA-SWG Scientific Meeting

TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop …

Continue Reading →